Erlocip (Erlotinib) 150 mg
4617₴
5057₴
-9%
Erlocip 150 mg is a targeted cancer therapy containing Erlotinib.
Manufacturer: Cipla (India). A premium generic equivalent of Tarceva.
Targeting EGFR Mutations:
Erlocip is an Epidermal Growth Factor Receptor (EGFR) inhibitor. It works best in patients whose cancer cells have specific genetic mutations (EGFR exon 19 deletion or exon 21 L858R substitution). By blocking these mutated signals, it halts tumor growth.
✅ Key Status: Standard of care for EGFR-positive Lung Cancer.
Indicated for the treatment of:
- Non-Small Cell Lung Cancer (NSCLC):
- First-line treatment for patients with EGFR activating mutations.
- Maintenance treatment for stable disease.
- Second or third-line treatment after chemotherapy failure.
- Pancreatic Cancer: In combination with Gemcitabine.
Strength: 150 mg tablet.
Standard Dosage (Lung Cancer): 150 mg once daily.
⚠️ CRITICAL ADMINISTRATION GUIDE:
- 🚫 Empty Stomach Only: Take at least 1 hour before or 2 hours after meals. Food increases drug exposure significantly, leading to severe toxicity.
- 🚬 Smoking Interaction: Smoking reduces plasma levels of Erlotinib by 50-60%. Smoking cessation is strongly advised.
- 💊 No PPIs: Avoid Omeprazole/Pantoprazole (they reduce drug absorption).
- Severe hepatic or renal impairment.
- Pregnancy (Category D) and breastfeeding.
- Severe hypersensitivity to Erlotinib.
Patients should expect:
- Acneiform Rash: Occurs in most patients. It is often a surrogate marker of efficacy (the rash means the drug is working).
- Diarrhea: Manage with Loperamide and hydration.
- Interstitial Lung Disease (ILD): Rare but serious. Report sudden coughing or fever immediately.
- Dry skin and brittle nails.
100% original product
Delivery across Ukraine
Customer reviews
What Customers Say
No reviews yet
Your review can be the first!